PT2206719E - Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno - Google Patents

Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno Download PDF

Info

Publication number
PT2206719E
PT2206719E PT101507630T PT10150763T PT2206719E PT 2206719 E PT2206719 E PT 2206719E PT 101507630 T PT101507630 T PT 101507630T PT 10150763 T PT10150763 T PT 10150763T PT 2206719 E PT2206719 E PT 2206719E
Authority
PT
Portugal
Prior art keywords
diene
methods
androsta
benzimidazole
beta
Prior art date
Application number
PT101507630T
Other languages
English (en)
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of PT2206719E publication Critical patent/PT2206719E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT101507630T 2005-03-02 2006-03-02 Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno PT2206719E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02

Publications (1)

Publication Number Publication Date
PT2206719E true PT2206719E (pt) 2015-02-05

Family

ID=36941503

Family Applications (2)

Application Number Title Priority Date Filing Date
PT06736460T PT1853619E (pt) 2005-03-02 2006-03-02 3-beta-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno para utilização no tratamento de uma doença da próstata
PT101507630T PT2206719E (pt) 2005-03-02 2006-03-02 Composição farmacêutica compreendendo 3-beta-hidroxi-17- (1-h-benzimidazol-1-il)androsta-5,16-dieno

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT06736460T PT1853619E (pt) 2005-03-02 2006-03-02 3-beta-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno para utilização no tratamento de uma doença da próstata

Country Status (22)

Country Link
US (1) US7875599B2 (pt)
EP (2) EP1853619B1 (pt)
JP (2) JP5130453B2 (pt)
KR (1) KR101380959B1 (pt)
CN (2) CN101155823A (pt)
AT (1) ATE482969T1 (pt)
AU (1) AU2006218711B2 (pt)
BR (1) BRPI0607523A2 (pt)
CA (1) CA2599953C (pt)
DE (1) DE602006017175D1 (pt)
DK (2) DK1853619T3 (pt)
EA (1) EA019560B1 (pt)
ES (2) ES2353413T3 (pt)
HK (1) HK1115387A1 (pt)
IL (3) IL185608A (pt)
MX (1) MX2007010593A (pt)
NZ (1) NZ561571A (pt)
PL (2) PL1853619T3 (pt)
PT (2) PT1853619E (pt)
SI (2) SI2206719T1 (pt)
WO (1) WO2006093993A1 (pt)
ZA (1) ZA200708106B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
ES2353413T3 (es) * 2005-03-02 2011-03-01 University Of Maryland 3-beta-hidroxi-17-(1h-bencimidazol-1-il)androsta-5,16-dieno para uso en el tratamiento de una enfermedad de la próstata.
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
GB2470873A (en) * 2008-03-12 2010-12-08 Univ Maryland Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20100048912A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) * 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
JP2012506906A (ja) * 2008-10-28 2012-03-22 バイオマリン ファーマシューティカル インコーポレイテッド デカヒドロ−1h−インデノキノリンおよびデカヒドロ−3h−シクロペンタフェナントリジノンcyp17インヒビター
EP2393827B1 (en) * 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
WO2010091299A2 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel combination cancer therapies
CA2765983C (en) 2009-06-26 2017-11-14 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
CA2770092A1 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
EP2499151A4 (en) * 2009-11-13 2013-03-20 Tokai Pharmaceuticals Inc MAMMALIAN STEROID METABOLITES
WO2011066582A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
CN103282358A (zh) * 2010-12-16 2013-09-04 生化马林制药公司 C-17-杂芳基类固醇化合物作为cyp11b、cyp17 及/或cyp21 抑制剂
KR20140025492A (ko) 2011-04-28 2014-03-04 노파르티스 아게 17α-히드록실라제/C17,20-리아제 억제제
BR112014001440A2 (pt) * 2011-07-18 2017-02-21 Tokai Pharmaceuticals Inc novas composições e métodos para o tratamento de câncer de próstata
EP2793896A4 (en) * 2011-12-22 2015-06-24 Tokai Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR POLYTHERAPY USING P13K / MTOR INHIBITORS
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
EP2991644B1 (en) * 2013-04-04 2020-03-25 University of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
EA030907B1 (ru) 2013-12-24 2018-10-31 Президент Энд Феллоус Оф Гарвард Колледж Аналоги кортистатина, их синтез и применения
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5,16-二烯-3-醇的盐及其制备方法
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
US10682362B2 (en) 2015-10-14 2020-06-16 Wayne State University Treatments and diagnostics for cancers
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
ES2700901B2 (es) * 2016-08-08 2019-08-06 Ind Chimica Srl Proceso para la preparación de 3ß-hidroxi-17-(1h-benzimidazol-1-il)androsta-5,16-dieno.
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
CA3089588A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
CA3087286C (en) * 2018-02-13 2023-06-27 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (pt) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
SI1660115T1 (sl) 2003-07-29 2011-10-28 Dompe Spa Farmacevtska kombinacija G-CSF in PLGF koristna za krvne matične celice
ES2353413T3 (es) 2005-03-02 2011-03-01 University Of Maryland 3-beta-hidroxi-17-(1h-bencimidazol-1-il)androsta-5,16-dieno para uso en el tratamiento de una enfermedad de la próstata.

Also Published As

Publication number Publication date
HK1115387A1 (pt) 2008-11-28
SI1853619T1 (sl) 2011-01-31
MX2007010593A (es) 2008-02-20
ATE482969T1 (de) 2010-10-15
ZA200708106B (en) 2008-12-31
KR101380959B1 (ko) 2014-04-04
US20080280864A1 (en) 2008-11-13
EP1853619B1 (en) 2010-09-29
AU2006218711A2 (en) 2006-09-08
JP5613206B2 (ja) 2014-10-22
EP1853619A4 (en) 2009-08-26
JP2008536807A (ja) 2008-09-11
EP2206719A3 (en) 2011-01-05
PL2206719T3 (pl) 2015-03-31
NZ561571A (en) 2009-09-25
IL210480A (en) 2015-06-30
IL210478A0 (en) 2011-03-31
PT1853619E (pt) 2011-01-03
SI2206719T1 (sl) 2015-03-31
CA2599953A1 (en) 2006-09-08
ES2528055T3 (es) 2015-02-03
EA200701872A1 (ru) 2008-06-30
US7875599B2 (en) 2011-01-25
DK2206719T3 (en) 2015-01-26
IL185608A (en) 2016-06-30
IL210480A0 (en) 2011-03-31
EP1853619A1 (en) 2007-11-14
CA2599953C (en) 2013-08-13
PL1853619T3 (pl) 2011-03-31
EP2206719A2 (en) 2010-07-14
EP2206719B1 (en) 2014-10-22
IL185608A0 (en) 2008-01-06
EA019560B1 (ru) 2014-04-30
ES2353413T3 (es) 2011-03-01
WO2006093993A1 (en) 2006-09-08
DE602006017175D1 (de) 2010-11-11
AU2006218711A1 (en) 2006-09-08
DK1853619T3 (da) 2011-01-10
CN101155823A (zh) 2008-04-02
KR20070120119A (ko) 2007-12-21
CN103349664A (zh) 2013-10-16
AU2006218711B2 (en) 2010-11-11
JP5130453B2 (ja) 2013-01-30
JP2012255026A (ja) 2012-12-27
BRPI0607523A2 (pt) 2009-09-08

Similar Documents

Publication Publication Date Title
PL2206719T3 (pl) Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
HUS1600021I1 (hu) MEK inhibitorok és módszerek azok felhasználására
HK1061354A1 (en) Synthesis of 4-amino-thalidomide enantiomers
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
TW200833695A (en) Use of spiro-oxindole compounds as therapeutic agents
WO2009120565A3 (en) Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
EP2044961A3 (en) Phospholipid analogues for the treatment of cancers
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
WO2005103010A3 (en) Pyrazole derivatives useful for the treatment of cancer
WO2007045060A8 (en) Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids